[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2726
1. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR): Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant; 2008 Dec;14(12):1323-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
  • To compare the clinical outcomes of older (age > or =55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged > or =55 years to 1949 NHL patients <55 years during the years 1990-2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):840-6 [18541205.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(2A):204-10 [10816029.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(7):737-41 [11042654.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):383-8 [12813446.001]
  • [Cites] Blood. 2003 Jul 1;102(1):31-5 [12595317.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27 [14750077.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Vital Health Stat 13. 1991 Sep;(108):1-236 [1720910.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1994 Oct 20;331(16):1063-7 [8090167.001]
  • [Cites] Bone Marrow Transplant. 1994 Dec;14(6):981-7 [7711677.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1327-32 [8648391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):18-25 [8996120.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):31-5 [9012928.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):671-8 [9156243.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1193-6 [9674850.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1273-8 [10414915.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1017-22 [16633361.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1166-71 [18272911.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • (PMID = 19041053.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-11; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83336; NLM/ PMC2638759
  •  go-up   go-down


2. Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA: The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology; 2010 Dec;19(12):1259-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors.
  • This study examines the association between the Impact of Cancer Version 2 Scales (IOCv2) and these outcomes in a large sample of survivors of adult non-Hodgkin lymphoma (NHL).
  • RESULTS: A total of 652 post-treatment NHL survivors participated.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] J Cancer Surviv. 2010 Mar;4(1):45-58 [19967410.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] BMJ. 2005 Mar 26;330(7493):702 [15695497.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4399-405 [15994149.001]
  • [Cites] Psychooncology. 2006 May;15(5):407-21 [16097041.001]
  • [Cites] Psychooncology. 2006 Sep;15(9):749-58 [16304622.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):895-903 [17245695.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):934-41 [18281667.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):891-900 [18050153.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 5;100(21):1530-41 [18957678.001]
  • [Cites] Am J Gastroenterol. 2002 May;97(5):1228-34 [12017152.001]
  • (PMID = 20099255.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101492; United States / NCI NIH HHS / CA / CA116339; United States / NCI NIH HHS / CA / CA016042; United States / AHRQ HHS / HS / T32-HS000032; United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / R03 CA101492-02; United States / NCI NIH HHS / CA / R25 CA116339; United States / AHRQ HHS / HS / T32 HS000032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS166749; NLM/ PMC2889206
  •  go-up   go-down


3. Smith SK, Zimmerman S, Williams CS, Zebrack BJ: Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer; 2009 Jul 15;115(14):3312-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health status and quality of life among non-Hodgkin lymphoma survivors.
  • BACKGROUND: : A growing body of evidence suggests that long-term survivors with 1 of the more common forms of adult cancer report a quality of life (QOL) similar to that in the general population.
  • Also, less is known concerning survivors of adult non-Hodgkin lymphoma (NHL), a disease often marked by alternating periods of disease and remission.
  • Therefore, in the current study, the authors compared the QOL status of individuals who reported having active NHL with the QOL status of individuals who were disease-free short-term survivors (STS) (2-4 years postdiagnosis) and long-term survivors (LTS) (> or =5 years postdiagnosis).
  • METHODS: Eligible survivors completed a mailed survey with validated measures, including physical and mental health status measured with the Medical Outcomes Study 36-item Short Form, cancer-related QOL, the Functional Assessment of Cancer Therapy-Lymphoma module, and self-reported impact of cancer.
  • CONCLUSIONS: Although survivors with NHL who had active disease reported more negative outcomes compared with off-treatment survivors, the length of time after diagnosis did not appear to matter with regard to outcomes for STS or LTS.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):537-42 [11733968.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2920-9 [12089220.001]
  • [Cites] J Anxiety Disord. 2002;16(2):195-206 [12194544.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Oncologist. 2003;8(4):342-9 [12897331.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Oncol Nurs Forum. 1995 Jul;22(6):915-22 [7567610.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] Psychooncology. 2005 Apr;14(4):307-17 [15386765.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4399-405 [15994149.001]
  • [Cites] Psychooncology. 2006 May;15(5):407-21 [16097041.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2355-62 [16649218.001]
  • [Cites] Psychooncology. 2006 Sep;15(9):749-58 [16304622.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2186-96 [17013914.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):934-41 [18281667.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):891-900 [18050153.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):948-53 [18213677.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • (PMID = 19452546.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / R03 CA101492-02; United States / NCI NIH HHS / CA / R03-CA-101492
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS124430; NLM/ PMC2718726
  •  go-up   go-down


Advertisement
4. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • The 395 NHL cases registered in Jamaica were matched by age, sex, calendar-year and HTLV serostatus to 309 controls from the same population.
  • Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


5. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV: Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol; 2008 Apr;83(4):279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.
  • Using allele-specific hybridization on the biochip 76 T-cell non-Hodgkin's lymphoma (NHL) patients, 83 B-cell chronic lymphocytic leukemia (B-CLL) patients, and 177 healthy donors were tested.
  • The GSTM1 null genotype was more frequent in NHL patients relative to controls (OR = 1.82, 95% CI = 1.1-3.1).
  • Thus, our findings show the association between polymorphic alleles of CYP1A1, GSTM1, and CYP2C9 genes and the risk to develop NHL or B-CLL.
  • [MeSH-major] Biotransformation / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Xenobiotics / pharmacokinetics
  • [MeSH-minor] Adult. Alleles. Arylamine N-Acetyltransferase / genetics. Carcinogens, Environmental / pharmacokinetics. Cytochrome P-450 Enzyme System / genetics. Female. Ferredoxin-NADP Reductase / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Humans. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Nucleic Acid Hybridization. Risk Factors. Russia / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18061941.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


6. Gemmati D, Ongaro A, Tognazzo S, Catozzi L, Federici F, Mauro E, Della Porta M, Campioni D, Bardi A, Gilli G, Pellati A, Caruso A, Scapoli GL, De Mattei M: Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica; 2007 Apr;92(4):478-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
  • We analyzed 110 patients with high-grade non-Hodgkin's lymphoma (NHL), 68 of whom were eligible for a chemotherapy combination containing methotrexate (MACOP-B) and 42 for chemotherapy without methotrexate (CHOP).
  • INTERPRETATION AND CONCLUSIONS: Our data suggest that MTHFR gene variants play a critical role in NHL outcome, possibly by interfering with the action of methotrexate with significant effects on toxicity and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Lymphoma, Large B-Cell, Diffuse / genetics. Methotrexate / pharmacokinetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Substitution. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug-Induced Liver Injury / epidemiology. Drug-Induced Liver Injury / etiology. Female. Genotype. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Mucositis / chemically induced. Mucositis / epidemiology. Prednisone / administration & dosage. Prednisone / adverse effects. Risk. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859137 for PMID:17488658 [PharmGKB] .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488658.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


7. Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC: Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors. J Clin Oncol; 2008 Feb 20;26(6):934-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.
  • Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable.
  • PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis.

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Fam Psychol. 2004 Sep;18(3):493-504 [15382974.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] Behav Res Ther. 1996 Aug;34(8):669-73 [8870294.001]
  • [Cites] Annu Rev Psychol. 1997;48:449-80 [9046566.001]
  • [Cites] J Trauma Stress. 1998 Apr;11(2):189-203 [9565911.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):177-82 [16862538.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):895-903 [17245695.001]
  • [Cites] Psychosomatics. 2001 Mar-Apr;42(2):133-40 [11239126.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] Psychooncology. 2002 Nov-Dec;11(6):479-94 [12476430.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • (PMID = 18281667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101492-01A2; United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / R03 CA101492-01A2; United States / NCI NIH HHS / CA / R03-CA-101492
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS261515; NLM/ PMC3025533
  •  go-up   go-down


8. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol; 2010 Apr;220(5):509-20
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab.
  • In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins.
  • The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / antagonists & inhibitors. Lymphoma, Large B-Cell, Diffuse / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087881.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 119
  •  go-up   go-down


9. Heerema NA, Bernheim A, Lim MS, Look AT, Pasqualucci L, Raetz E, Sanger WG, Cairo MS: State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer; 2005 Oct 15;45(5):616-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY.
  • BACKGROUND: A significant number of studies describe the cytogenetics and molecular genetics of adult non-Hodgkin lymphoma (NHL); however, similar knowledge is lacking regarding pediatric NHL.
  • METHODS: A workshop to discuss the "State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays" in pediatric NHL was held in conjunction with the First International Symposium on Childhood and Adolescent Non-Hodgkin Lymphoma on April 9, 2003 in New York City.
  • RESULTS: Cytogenetic characteristics of pediatric NHL include 14q11.2 rearrangements in T-cell lymphoblastic leukemia/lymphomas (LBL), ALK rearrangements in anaplastic large cell lymphomas (ALCL), and CMYC translocations in both Burkitt and Burkitt-like lymphomas (BL/BLL).
  • Pediatric diffuse large B-cell lymphoma (DLBCL) is cytogenetically different from DLBCL in adults, suggesting a different disease in children.
  • CONCLUSIONS: Additional cytogenetic, molecular and microarray investigations of NHL in children are vital to better understand these diseases, their etiology, and differences from adult NHL.
  • A greater understanding of pediatric NHL will lead to disease-specific and patient-individualized therapies of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Basic Helix-Loop-Helix Transcription Factors. Burkitt Lymphoma / genetics. Child. Cytogenetic Analysis. DNA-Binding Proteins / genetics. Gene Rearrangement. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Microarray Analysis. Molecular Biology. Neoplasm Proteins / genetics. Oncogene Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127683.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13-CA10195-01
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LYL1 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / STIL protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


10. Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, Kim WS, Kim SJ: Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol; 2009 Nov;88(11):1099-106
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
  • Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce.
  • We report our results using the LMB protocol on Korean adult BL patients.
  • All of the non-CR patients died, including five PR and one with progressive disease.
  • In conclusion, the LMB protocol was effective for Korean adult BL patients.
  • However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Evaluation. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sepsis / epidemiology. Sepsis / etiology. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288103.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El-Desoky H, Saleh R, Moussa MA: The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Biol Trace Elem Res; 2007;120(1-3):1-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin's lymphoma (NHL).
  • Fifty patients with newly diagnosed NHL were randomly divided into two groups.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Sodium Selenite / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Down-Regulation. Doxorubicin / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916949.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; HIW548RQ3W / Sodium Selenite; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M: [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions]. Orv Hetil; 2009 Aug 30;150(35):1649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
  • [Transliterated title] Pimer gastrointestinalis non-Hodgkin-lymphoma két magyarországi régió beteganyaga alapján.
  • Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased.
  • The treatment strategy for non-Hodgkin's lymphoma has changed over the past decade: chemo-immunotherapy has largely taken over surgical intervention, the dominant treatment option of the past.
  • METHODS: The authors present their experience with 48 patients with non-Hodgkin's lymphoma, affecting the gastrointestinal tract, treated in Kaposvár, in the Kaposi Mór Teaching Hospital and in Gyula, in the Pándy Kálmán County Hospital.
  • RESULTS: The most frequently involved GI organ was the stomach ( n = 26), with the dominant histological type of diffuse large B-cell lymphoma.
  • Patients with upper gastrointestinal tract involvement carried the best prognosis (IPI: 2.0); at the same time, patients with stomach lymphoma achieved the highest rate of remission (73%).
  • CONCLUSIONS: With chemo-immunotherapy the chances of a complete remission have significantly improved over the past decade, thus a significant portion of non-Hodgkin's lymphomas involving the gastrointestinal tract can be cured.
  • IPI index represents the most recognised indicator for assessing the prognosis of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Hungary / epidemiology. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692309.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


13. Yayan J, Mallouhi A, Moser P, Irschick E: [Non-Hodgkin lymphoma of the lacrimal gland]. Ophthalmologe; 2008 Sep;105(9):852-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma of the lacrimal gland].
  • [Transliterated title] Non-Hodgkin-Lymphom der Tränendrüse.
  • BACKGROUND: Non-Hodgkin lymphoma is a systemic disease and various organs can therefore be affected.
  • Ocular manifestations of non-Hodgkin lymphomas are possible but involvement of the eyelids or lacrimal glands are uncommon.
  • The histologic examination revealed a recurrent non-Hodgkin lymphoma.
  • In the case described here it was interesting that behind a painless eyelid swelling even a systemic disorder was hidden, i.e. a recurrence of a non-Hodgkin lymphoma, which was localized in the lacrimal gland.
  • [MeSH-major] Eye Neoplasms. Lacrimal Apparatus. Lymphoma, Follicular
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Diagnosis, Differential. Edema / etiology. Eyelid Diseases / etiology. Female. Humans. Immunotherapy. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Rituximab. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373097.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Henderson TO, Hlubocky F, Diller L, Daugherty C: Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol; 2009 May 20;27(15_suppl):6561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A second mailing for non-responders is planned.
  • 84% of respondents report eventually referring CCS to a LTFU program (40%), to a primary care physician (23%) or to an adult oncologist (12%).
  • In a clinical vignette of 29 year old women exposed to mantle radiation and anthracyclines (150 mg/m2) for Hodgkin's lymphoma at 16 years of age: 30% of respondents did not appropriately recommend yearly breast cancer surveillance (based on Children's Oncology Group LTFU guidelines); 41% of respondents did not appropriately recommend cardiac surveillance; and 15% of respondents did not appropriately recommend yearly thyroid screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tan H, Tomic K, Daniel G, Hurley D, Barron R: Evaluating risk of hospitalization with G-CSF use in real-world oncology practice. J Clin Oncol; 2009 May 20;27(15_suppl):6626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • Peripheral arterial tonometry (PAT) is a non-invasive technique that measures endothelial function (EF), as a surrogate marker of sub-clinical atherosclerosis.
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dögel D, Beuing O, Koenigsmann M, Diete S: [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr; 2008 Jan;76(1):41-6
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
  • [Transliterated title] Paraneoplastische Limbische Enzephalitis als Erstmanifestation eines malignen Non Hodgkin Lymphoms.
  • PLE is most frequently associated with certain carcinomas, but its occurrence with Hodgkin lymphoma has also been recognized.
  • Association with non-Hodgkin lymphoma has only been occasionally reported in single cases.
  • We report two additional patients, in whom malignant non-Hodgkin lymphomas of the B- and T-cell lines were detected.
  • [MeSH-major] Limbic Encephalitis / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189222.001).
  • [ISSN] 0720-4299
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


19. Setty BA, Termuhlen AM: Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep; 2010 Jul;5(3):163-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pediatric non-hodgkin lymphoma.
  • Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults.
  • Understanding of these rare types of NHL comes from small pediatric case series or the adult literature.
  • Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Child. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20490722.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


20. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL).
  • The recognition that different NHL subtypes require different treatment strategies was fundamental to developing successful therapy regimens.
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • For children with B-NHL, a strategy of rapidly repeated short, dose-intense courses proved more efficacious, with EFS rates up to 90%.
  • A variety of new treatment options, some already established for treating adult NHL, await evaluation in childhood NHL.


21. Smedby KE, Hjalgrim H, Chang ET, Rostgaard K, Glimelius B, Adami HO, Melbye M: Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res; 2007 Nov 15;67(22):11074-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood social environment and risk of non-Hodgkin lymphoma in adults.
  • Better hygiene and sanitation and decreasing family size parallel the increasing incidence of non-Hodgkin lymphoma (NHL) in many populations around the world.
  • However, whether sibship size, birth order, and crowding are related to adult NHL risk is not clear.
  • We investigated how family structure and childhood social environment were related to the risk of NHL and NHL subtypes in a large Scandinavian population-based case control study with 6,242 participants aged 18 to 74 years.
  • Having four or more siblings was associated with a moderately increased risk of NHL, compared with having no siblings (OR 1.34, 95% CI 1.11-1.62, P(trend) < 0.001).
  • High household crowding was also positively associated with risk of NHL.
  • Results were slightly stronger for diffuse large B-cell and T-cell lymphomas than for other major NHL subtypes.
  • Our findings add to the evidence that large sibship size, late birth order, and childhood crowding are associated with an elevated risk of NHL.
  • [MeSH-major] Environment. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Denmark. Female. Humans. Male. Middle Aged. Odds Ratio. Risk. Risk Factors. Social Class. Sweden


22. Halilbasić A, Mesic E, Cikusić E, Arnautović A: [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]. Med Arh; 2006;60(6 Suppl 2):78-83
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease].
  • [Transliterated title] Non Hodgkin limfom u Sjeveroistoinoj Bosni--promjene u bioloskoj agresivnosti i nacinu primarne prezentacije.
  • INTRODUCTION: NHL are the group of lymphoproliferative neoplasms which incidence is in constant increase.
  • The aim of the paper is the analysis of the immunophenotypes, clinical distribution and ways of primary presentation and biological aggressiveness of NHL in the North-East Bosnia.
  • METHODS: Two hundred and twenty-eight patients with pathohistologically proved NHL are analysed in the paper.
  • The tested group consisted of 142 patients with diagnosed NHL in the period between 1998 and 2002, and the control group consisted of 86 patients whose NHL was proved in the period between 1987 and 1991.
  • These factors were analysed: immunophenotype NHL by immunohistochemical method of indirect three-stage immunoperoxidase with streptovidin, the type of NHL, the degree of biological aggressiveness of NHL, the way of primary presentation and the clinical phases of distribution of the disease according to the age, sex, profession and the habitat (urban or rural) of the patients.
  • RESULTS: The total number of patients with NHL in the North-East Bosnia was quite bigger in the test group than in the control group with the incidence of 2.6/100,000 inhabitants in 1989, and 6.91/100,000 inhabitants in 2002.
  • Diffuse Large Cell Lymphoma (DLCL) was dominant in the test group with total of 73 patients (51%), and Small Cell Lymphoma was dominant in the control group with total of 33 patients (38%).
  • Statistically significant increase of both DLCL and MALT lymphoma is found in the test group (p < 0.025), and the most frequent were patients with IV-B (18%), I-AE (15%) and II-BE (12%) clinical stadium, while in the control group the most frequent number of patients was in the clinical studia III-B (19%), II-B (14%) and IV-B (14%).
  • In the test group there was a significant increase of aggressive lymphoma in both men and women (p < 0.01).
  • DISCUSSION: In recent years, all NHL studies have shown an increase of the incidence in patients, especially in older age while the increase is not found only in infants.
  • In our study the highest percentage of the incidence of NHL occurs in patients who are 55 and older that exactly matches the literature date.
  • In the test group the number of MALT and DLCL lymphoma located in stomach is in increase.
  • In the last few years the dominant type of NHL worldwide is DLCL.
  • The continuous increase of patients with aggressive NHL in the recent years has been noticed especially Lukavac, Tuzla and Zivinice.
  • CONCLUSION: The incidence of NHL in the region of the North East Bosnia follows the world trend of the general increase of the NHL incidence including the significant increase in number of aggressive lymphoma.
  • The frequency of DLCL and MALT lymphoma is evidently in increase.
  • B phenotype of NHL is predominant in both periods of testing.
  • [MeSH-major] Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Bosnia and Herzegovina / epidemiology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172989.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


23. Constantin V, Socea B, Moculescu C, Sireţeanu G, Popa F: [Enteral non-Hodgkin lymphoma in young age--difficult diagnosis]. Chirurgia (Bucur); 2009 Sep-Oct;104(5):607-10
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enteral non-Hodgkin lymphoma in young age--difficult diagnosis].
  • [Transliterated title] Limfom non-Hodgkinian forma enterală la tânăr, caz subdiagnosticat.
  • Among all histopathologic forms of malignant colonic tumors treated in our Clinic, lymphoma is the fifth as frequency of apparition, respectively the fourth at patients less than 40 years old.
  • We present the case of a 22-years-old patient, having colonic polyposis and multicentric non-Hodgkin lymphoma of the terminal ileum and ascending colon.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Ileal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / diagnosis. Adult. Colectomy / methods. Colon, Ascending / pathology. Diagnosis, Differential. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943562.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


24. Beck Z, Illés A, Keresztes K, Bessenyei B, Szöllosi Z, Kis A, Oláh E: [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?]. Orv Hetil; 2006 Aug 20;147(33):1539-44
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
  • [Transliterated title] Az Epstein-Barr-vírus ZEBRA fehérjéjének expressziója magyarországi Hodgkin-lymphomás betegekben: latens vagy litikus ciklus?
  • The virus is associated with an increasing number of lymphoid malignancies, such as Hodgkin and non-Hodgkin lymphomas.
  • Although the presence of ZEBRA protein induces lytic cycle, some lymphoma cases show this protein expression.
  • AIM: In our present study we investigated the frequency of expression of ZEBRA protein in Hungarian patients with Hodgkin lymphoma associated with Epstein-Barr virus infection.
  • The authors wanted to clarify whether this expression is specific to latency type II or occurs in some non-Hodgkin lymphoma cases with latency type III as well.
  • METHOD: 109 HL and 59 NHL were studied for the presence of the virus in the tumor and for expression of the latency proteins and ZEBRA by immunohistochemistry.
  • We detected the weak expression of ZEBRA protein in 13 of the 25 LMP1 positive Hodgkin lymphoma cases and in 6 of the 18 LMP1 positive non-Hodgkin lymphoma samples.
  • [MeSH-major] DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / virology. Trans-Activators / analysis. Viral Proteins / analysis
  • [MeSH-minor] Adult. Aged. Epstein-Barr Virus Nuclear Antigens / analysis. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Hungary. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037676.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA-Binding Proteins; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  •  go-up   go-down


25. Rafai MA, Boulaajaj FZ, Moutawakkil BE, Bourezgui M, Sibai M, Sahnoun A, Naja A, Azhari A, Slassi I: [Cauda equina syndrome leading to diagnosis of malignant non-Hodgkin lymphoma of the spine]. Presse Med; 2008 May;37(5 Pt 1):787-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cauda equina syndrome leading to diagnosis of malignant non-Hodgkin lymphoma of the spine].
  • [Transliterated title] Syndrome de la queue de cheval révélant un lymphome malin non hodgkinien vertébral.
  • INTRODUCTION: Malignant non-Hodgkin lymphoma is a lymphoid proliferation.
  • CASE: We report a case in which cauda equina syndrome in a 29-year-old man led to the diagnosis of a painless non-Hodgkin lymphoma of the spine.
  • DISCUSSION: Infiltration of the cauda equina roots is rare in malignant non-Hodgkin lymphoma and raises problems for positive diagnosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Polyradiculopathy / etiology. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Male. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201863.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Yi WS, Xu XL, Xiang Q, Jiang HB: [Characteristics of ocular adnexal non-Hodgkin lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;33(9):826-30
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of ocular adnexal non-Hodgkin lymphoma].
  • OBJECTIVE: To investigate the clinical manifestation and pathological features of primary ocular adnexal non-Hodgkin lymphoma.
  • METHODS: Data of 18 patients with biopsy-proven ocular adnexal non-Hodgkin lymphoma at Xiangya hospital were reviewed.The disease site, clinical manifestation,imaging and pathological features of the tumor were summarized.
  • RESULTS: All patients had typical presentation of an adnexal mass.Twelve(66.7%) patients had orbital involvement, 3(16.7%) had conjunctival, and 3(16.7%) had lymphoma involving the eyelids.Eight patients were misdiagnosed as "inflammatory pseudotumour" before the operation according to their clinical and imaging examination,another 8 patients were diagnosed as "ocular adnexal tumour with unknown nature" before the operation.
  • According to the pathologic diagnosis, 16 patients (88.9%)had marginal zone lymphomas of mucosa-associated lymphoid tissue(MZL-MALT) and 2 (11.1%) had NK/T-cell lymphoma.
  • CONCLUSION: The typical presentation of ocular adnexal lymphoma is a painless mass.Orbital connective tissue is the most involved anatomical site.
  • The diagnosis of ocular adnexal non-Hodgkin lymphoma is difficult which could easily be misdiagnosed as "inflammatory pseudotumour".
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812662.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


27. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • 10 patients with partial remission and 5 non-responders were continually treated.
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


28. Mioulet D, Braem L, Heno P, Paule P, Peloni JM, Bonnet D, Fourcade L: [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter]. Ann Cardiol Angeiol (Paris); 2009 Apr;58(2):117-21
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter].
  • [Transliterated title] Flutter atrial révélateur de l'extension cardiaque d'un lymphome malin non hodgkinien.
  • Our case report, which is a slow atrial flutter with a pericardial effusion, is an uncommon discovery mode for a malignant lymphoma.
  • Their diagnosis and the mechanism of the arythmia were allowed by non-invasive cardiac imagery (transesophageal echography and magnetic resonance imaging), which showed a tumour-like infiltration of the right atrium, of the right ventricle posterior wall, and of the atrioventricular junction.
  • The diagnosis of a high grade B cell malignant non-hodgkin lymphoma, involving the bone marrow, the liver and the kidneys was made by biopsies of lymph nodes, histological analysis of the bone marrow, and a body CT scan.
  • However, the patient passed away, due to neurological complications 13 months after the diagnosis of lymphoma, without recurrence of cardiac involvement.
  • [MeSH-major] Atrial Flutter / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657797.001).
  • [ISSN] 1768-3181
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Sharma A, Gupta D, Mohanti BK, Thulkar S, Dwary A, Goyal S, Muzumder S, Das P: Non-Hodgkin lymphoma following temozolomide. Pediatr Blood Cancer; 2009 Oct;53(4):661-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma following temozolomide.
  • Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported.
  • We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy.
  • She developed lymphoma 2 months after completing chemoradiotherapy.
  • Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Dacarbazine / analogs & derivatives. Lymphoma, Non-Hodgkin / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Adult. Female. Glioblastoma / drug therapy. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533661.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


30. Wiecheć M, Kempf Haber M, Załuska A, Klimek M, Skotnicki AB: [Non Hodgkin lymphoma during pregnancy]. Ginekol Pol; 2005 Feb;76(2):135-40
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma during pregnancy].
  • The coexistence of Non Hodgkin Lymphoma and pregnancy has been rarely reported.
  • We are describing the case of 26-year-old pregnant woman, to whom two chemotherapy courses were administered because of the lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Pregnancy. Remission Induction. Transplantation, Autologous


31. Patte C, Ribrag V, Brugières L: [Non Hodgkin's lymphoma in adolescents]. Bull Cancer; 2007 Apr;94(4):339-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in adolescents].
  • [Transliterated title] Problématique de la prise en charge des adolescents atteints de lymphomes non hodgkiniens.
  • In France, adolescents (15-20 years) with non Hodgkin's lymphoma (NHL) are referred either to paediatric or to adult onco-haematological departments.
  • According to data obtained from regional tumour registries (covering about 10% of France), their 5 year survival rate was 59% whereas it was 87% for children (< or =14 years) treated for NHL during a similar period of time.
  • We reviewed the management of NHL either by the paediatricians or the onco-hematologists for adults.
  • The categories of NHL that are reviewed and whose clinical and biological characteristics are presented are: Burkitt, lymphoblastic and large cell, either B or anaplastic.
  • Further studies specific to the adolescents are needed to better know the biology of their lymphoma and to determine the best therapeutic approach.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Child. Clinical Protocols. France / epidemiology. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Medical Oncology / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449436.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 72
  •  go-up   go-down


32. Gross TG, Termuhlen AM: Pediatric non-Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):167-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually.
  • NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes.
  • Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy.
  • This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Curr Oncol Rep. 2007 Nov;9(6):459-65 [17991353.001]
  • (PMID = 20425462.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Padilla GF, Garibay MA, Hummel HN, Avila R, Méndez A, Ramírez R: [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review]. Acta Gastroenterol Latinoam; 2009 Jun;39(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review].
  • [Transliterated title] Linfoma no Hodgkin fulminante presentándose con acidosis láctica e insuficiencia hepática aguda: reporte de caso y revisión de la literatura.
  • Hematological malignancies, as leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma, typically do not result in hepatic dysfunction and rarely manifest as fulminant liver failure.
  • CONCLUSIONS: Acute liver failure is uncommon as the presenting feature of lymphoma.
  • Given the poor prognosis associated with late or missed diagnosis and the potential benefits of early chemotherapy, lymphoma should be considered in any patient presenting with acute liver failure without an obvious etiology and associated with lactic acidosis and hepatomegaly.
  • [MeSH-major] Acidosis, Lactic / etiology. Liver Failure, Acute / etiology. Liver Neoplasms / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663087.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 41
  •  go-up   go-down


34. Dalton SO, Poulsen AH, Nørgaard M, McLaughlin JK, Johansen C, Friis S: Tricyclic antidepressants and non-Hodgkin lymphoma. Epidemiology; 2008 Jul;19(4):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tricyclic antidepressants and non-Hodgkin lymphoma.
  • BACKGROUND: An increased risk of non-Hodgkin lymphoma (NHL) has been reported among long-term users of tricyclic antidepressants.
  • METHODS: The incidence of NHL among 43,932 users of any antidepressant medication (2 or more prescriptions) in the county of North Jutland, Denmark, during 1989-2003 was compared with NHL incidence in all those not using antidepressants (0 or 1 prescription).
  • RESULTS: Use of tricyclic antidepressants was associated with an overall increased incidence of NHL (adjusted incidence rate ratio [IRR] = 1.53; 95% confidence interval [CI] = 1.06-2.21) compared with nonuse.
  • Users of other types of antidepressants were not at increased risk of NHL.
  • CONCLUSIONS: Our results indicate an increased risk of non-Hodgkin lymphoma specifically among long-term users of tricyclic antidepressant medications.
  • [MeSH-major] Antidepressive Agents, Tricyclic / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Denmark / epidemiology. Humans. Incidence. Poisson Distribution. Registries. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552589.001).
  • [ISSN] 1531-5487
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic
  •  go-up   go-down


35. Grulich AE, Vajdic CM: The epidemiology of non-Hodgkin lymphoma. Pathology; 2005 Dec;37(6):409-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) includes a group of more than 20 different malignant lymphoproliferative diseases that originate from lymphocytes.
  • Rates of NHL have increased dramatically over the past few decades, although the rate of increase has recently slowed.
  • The causes of the increase in NHL rates are largely unknown.
  • The best described risk factor for NHL is immune deficiency; rates of NHL are greatly increased, with relative risks of 10-100 or more, in people with immune deficiency associated with immune suppressive therapy after transplantation, HIV/AIDS, and congenital conditions.
  • In addition, some NHL subtypes are associated with specific infections.
  • These include immune-deficiency-associated central nervous system NHL (Epstein-Barr virus); gastric mucosa-associated lymphoid tissue NHL (Helicobacter pylori); adult T-cell leukemia/lymphoma (human T-lymphotrophic virus type 1) and body cavity-based lymphoma (human herpesvirus 8).
  • However, these specific infections account for a very small proportion of total NHL incidence.
  • In addition to immune deficiency and infection, other immune-related conditions are increasingly being recognised as related to NHL risk.
  • Specific autoimmune conditions, including rheumatoid arthritis, systemic lupus erythema, Sjogren's syndrome, psoriasis and coeliac disease are associated with moderately increased risk of NHL.
  • On the other hand, allergic and atopic conditions and their correlates such as early birth order, appear to be associated with a decreased risk of NHL.A variety of other exposures are less strongly related to NHL risk.
  • Recently, two studies have reported that sun exposure is associated with a decreased risk of NHL.
  • Smoking appears to be weakly positively associated with risk of follicular NHL, and alcohol intake is associated with a decreased risk of NHL.
  • The pooled analysis of several case-control studies of NHL risk that are currently in the field promises to help clarify which of these risk factors are real, and will contribute to the elucidation of the mechanisms of how disorders of the immune system, and other factors, are related to NHL risk.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373224.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 147
  •  go-up   go-down


36. Spinelli JJ, Ng CH, Weber JP, Connors JM, Gascoyne RD, Lai AS, Brooks-Wilson AR, Le ND, Berry BR, Gallagher RP: Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer; 2007 Dec 15;121(12):2767-75
Hazardous Substances Data Bank. OXYCHLORDANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorines and risk of non-Hodgkin lymphoma.
  • Organochlorine chemicals and polychlorinated biphenyls (PCBs) have been suspected as possible risk factors for non-Hodgkin lymphoma (NHL).
  • We investigated PCBs and organochlorine pesticides and risk of NHL in a population-based case-control study in British Columbia, Canada.
  • Several dioxin-like PCB congeners were associated with increased risk of NHL, including dioxin-like PCB nos.
  • Several non-dioxin-like congeners also showed significant associations.
  • Six pesticide analytes also showed a significant association with NHL; beta-hexachlorocyclohexane, p,p'-DDE, hexachlorobenzene, mirex, oxychlordane and trans-nonachlor.
  • Our results provide further evidence that organochlorines contribute to NHL risk.
  • [MeSH-major] Environmental Exposure / adverse effects. Environmental Pollutants / blood. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / epidemiology. Pesticides / blood. Polychlorinated Biphenyls / blood
  • [MeSH-minor] Adult. Aged. British Columbia / epidemiology. Case-Control Studies. Chlordan / analogs & derivatives. Chlordan / blood. Female. Humans. Hydrocarbons, Chlorinated / blood. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Registries. Risk Assessment. Risk Factors. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17722095.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides; 12789-03-6 / Chlordan; 27304-13-8 / oxychlordane; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


37. Linet MS, Taggart T, Severson RK, Cerhan JR, Cozen W, Hartge P, Colt J: Cellular telephones and non-Hodgkin lymphoma. Int J Cancer; 2006 Nov 15;119(10):2382-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular telephones and non-Hodgkin lymphoma.
  • Dramatic increase in hand-held cellular telephone use since the 1980s and excess risk of lymphoproliferative malignancies associated with radio-frequency radiation (RFR) exposures in epidemiological and experimental studies motivated assessment of cellular telephones within a comprehensive US case-control investigation of non-Hodgkin lymphoma (NHL).
  • A questionnaire ascertained cellular telephone use in 551 NHL cases and 462 frequency-matched population controls.
  • Among regular users compared to those who had never used hand-held cellular telephones, risks of NHL were not significantly associated with minutes per week, duration, cumulative lifetime or year of first use, although NHL was non-significantly higher in men who used cellular telephones for more than 8 years.
  • Little evidence linked use of cellular telephones with total, diffuse large B-cell lymphoma or follicular NHL.
  • [MeSH-major] Cell Phones. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Odds Ratio. Sex Distribution. Surveys and Questionnaires. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894556.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N02-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P: Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood; 2008 Dec 15;112(13):5150-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic heterogeneity among non-Hodgkin lymphoma subtypes.
  • Understanding patterns of etiologic commonality and heterogeneity for non-Hodgkin lymphomas may illuminate lymphomagenesis.
  • We present the first systematic comparison of risks by lymphoma subtype for a broad range of putative risk factors in a population-based case-control study, including diffuse large B-cell (DLBCL; N = 416), follicular (N = 318), and marginal zone lymphomas (N = 106), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).
  • Autoimmune conditions increased risk for marginal zone lymphoma alone.
  • The tumor necrosis factor G-308A polymorphism (rs1800629) increased risks for both DLBCL and marginal zone lymphoma.
  • We observed no significant risk factors for follicular lymphoma alone.
  • These data clearly support both etiologic commonality and heterogeneity for lymphoma subtypes, suggesting that immune dysfunction is of greater etiologic importance for DLBCL and marginal zone lymphoma than for CLL/SLL and follicular lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):953-64 [16221809.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):293-7 [16113054.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):516-25 [15951670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):251-7 [16492912.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):47-55 [16731576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1281-6 [16835324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1287-94 [16835325.001]
  • [Cites] Pharmacogenet Genomics. 2006 Aug;16(8):537-45 [16847422.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3161-7 [16857995.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2477-87 [17169793.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):268-74 [17270016.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):652-9 [17204518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):159-68 [11936822.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S42-5 [12142961.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):694-704 [12209158.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):148-54 [14718216.001]
  • [Cites] Genes Immun. 2004 Aug;5(5):315-29 [14973548.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Mutat Res. 1975 Dec;31(6):347-64 [768755.001]
  • [Cites] Carcinogenesis. 1987 May;8(5):665-8 [3581424.001]
  • [Cites] Jpn J Cancer Res. 1989 Dec;80(12):1176-8 [2516847.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):295-301 [1497384.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2221-7 [8895492.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):545-51 [10223180.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1951-8 [10371587.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3050-9 [17119116.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1365-72 [17481729.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1180-5 [17666372.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):888-94 [18506687.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1203-14 [16215871.001]
  • (PMID = 18796628.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N02-PC-71105; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; None / None / / N01 PC065064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2597610
  •  go-up   go-down


39. Colt JS, Severson RK, Lubin J, Rothman N, Camann D, Davis S, Cerhan JR, Cozen W, Hartge P: Organochlorines in carpet dust and non-Hodgkin lymphoma. Epidemiology; 2005 Jul;16(4):516-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorines in carpet dust and non-Hodgkin lymphoma.
  • BACKGROUND: The incidence of non-Hodgkin lymphoma (NHL) has risen over the past several decades.
  • METHODS: In this population-based case-control study, we examined NHL risk and exposure to organochlorine compounds using concentrations in carpet dust as an exposure indicator.
  • We identified NHL cases, uninfected with HIV, diagnosed between 1998 and 2000 among women and men ages 20-74 years in Iowa, Los Angeles County, and the Detroit and Seattle metropolitan areas.
  • RESULTS: NHL risk was elevated if any of the polychlorinated biphenyl (PCB) congeners (PCBs 105, 138, 153, 170, or 180) was detected (odds ratio = 1.5; 95% confidence interval = 1.2-2.0).
  • NHL risk was elevated if dichlorodiphenyldichloroethylene (DDE) was detected (1.3; 1.0-1.7), but only among men.
  • CONCLUSIONS: Our findings suggest an increased risk of NHL associated with exposure to PCBs, with evidence of greater effects for PCB 180.
  • [MeSH-major] Dust. Environmental Exposure / adverse effects. Environmental Pollutants / toxicity. Floors and Floorcoverings. Hydrocarbons, Chlorinated / toxicity. Lymphoma, Non-Hodgkin / chemically induced
  • [MeSH-minor] Adult. Aged. Case-Control Studies. European Continental Ancestry Group. Female. Humans. Male. Middle Aged. Pesticides / toxicity. Regression Analysis. SEER Program. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951670.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67008; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / CP / N02-CP-19114; United States / NCI NIH HHS / CP / N02-CP-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dust; 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides
  •  go-up   go-down


40. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol; 2009 Jan;144(1):24-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
  • Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15-19 year age group.
  • Hodgkin lymphoma (HL) accounts for the majority (two-thirds) of cases, while the remainder of patients have one of four subtypes of non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL).
  • Epidemiology, histology, treatment and outcome differ between HL and NHL, as well as among the various subtypes of NHL.
  • Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma.
  • This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Humans. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087093.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 115
  •  go-up   go-down


41. Benharroch D, Einav I, Feldman A, Levy A, Ariad S, Gopas J: Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited. APMIS; 2010 May;118(5):339-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited.
  • We scrutinized the role of apoptosis of the Hodgkin-Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) and critically reviewed its features in the light of conflicting evidence.
  • These findings support our contention that the role of apoptosis in the HRS cells of Hodgkin lymphoma has not been completely elucidated and is at variance with that in the consensus.
  • [MeSH-major] Apoptosis / physiology. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Herpesvirus 4, Human / metabolism. Herpesvirus 4, Human / pathogenicity. Humans. Immunohistochemistry. Male. Middle Aged. NF-kappa B / metabolism. Viral Matrix Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477808.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  • [Number-of-references] 29
  •  go-up   go-down


42. Melbye M, Smedby KE, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, Schöllkopf C, Sundström C, Chang ET, Koskela P, Adami HO, Hjalgrim H: Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst; 2007 Jan 17;99(2):158-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy and risk of non-Hodgkin lymphoma.
  • BACKGROUND: A possible connection between allergy and cancer has been suspected, but allergy-related conditions or atopy have been inconsistently associated with reduced risks of non-Hodgkin lymphoma.
  • METHODS: We carried out a population-based study of 3055 case patients with non-Hodgkin lymphoma and 3187 control subjects in Denmark and Sweden, including questionnaire information on allergy and blood specimens, and a nested case-control study within a prospective cohort of more than 400,000 Finnish women.
  • In the second study, serum specimens from the 198 case patients who developed non-Hodgkin lymphoma within a median of 8.9 years after the blood was drawn were matched with serum specimens from 594 control subjects.
  • RESULTS: In the first study, ever having hay fever, but not other allergic conditions, was associated with a reduced risk of non-Hodgkin lymphoma.
  • In particular, subjects with specific IgE reactivity in serum had a 32% (95% CI = 20% to 42%) lower risk of overall non-Hodgkin lymphoma than those without such reactivity.
  • In the second (i.e., prospective) study, no association was found between non-Hodgkin lymphoma and specific IgE reactivity, except possibly immediately before a diagnosis of non-Hodgkin lymphoma (> or = 10 years before diagnosis, OR = 1.00, 95% CI = 0.48 to 2.09; 5-9 years before, OR = 0.95, 95% CI = 0.50 to 1.84; 1-4 years before, OR = 0.33, 95% CI = 0.11 to 1.02; and < 1 year before, OR = 0.27, 95% CI = 0.03 to 2.31).
  • CONCLUSION: Allergy may not be causally associated with the risk of non-Hodgkin lymphoma.
  • The inverse association observed in some case-control studies may arise because non-Hodgkin lymphoma suppresses the immunologic response to allergens.
  • [MeSH-major] Hypersensitivity, Immediate / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Denmark / epidemiology. Female. Finland / epidemiology. Humans. Immunoglobulin E / immunology. Logistic Models. Male. Middle Aged. Odds Ratio. Prospective Studies. Retrospective Studies. Rhinitis, Allergic, Perennial / complications. Risk Assessment. Risk Factors. Selection Bias. Surveys and Questionnaires. Sweden / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Sep 19;99(18):1417 [17848674.001]
  • (PMID = 17227999.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R03 CA 101496-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


43. Scotti SD, Laudadio J: Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET. J Radiol Case Rep; 2009;3(8):18-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.
  • Testicular relapse of leukemia and lymphoma is a well-recognized phenomenon, with testicular relapse of lymphoma being more common in the adult population and leukemia relapse being more common in the pediatric population.
  • With the advent of F-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the evaluation of lymphoma it is possible to evaluate testicular uptake of FDG and to detect primary testicular lymphoma or testicular relapse on the FDG-PET examination.
  • Testicular relapse of non-Hodgkin lymphoma (NHL) detected on FDG-PET has been reported previously.
  • Elevated activity or lateralizing activity should be viewed with suspicion, with etiologies including primary testicular tumor, primary or secondary testicular lymphoma and metastatic disease with other etiologies less likely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vivo. 1991 May-Jun;5(3):297-9 [1893083.001]
  • [Cites] Lancet Oncol. 2002 Jun;3(6):357-63 [12107023.001]
  • [Cites] Cancer. 1969 Jun;23(6):1290-5 [5818886.001]
  • (PMID = 22470678.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303329
  • [Keywords] NOTNLM ; Non-Hodgkin’s Lymphoma / PET / PET/CT / testicular lymphoma
  •  go-up   go-down


44. Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami HO, Glimelius B, Hjalgrim H, Melbye M: Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma. Int J Cancer; 2009 Jun 1;124(11):2616-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.
  • Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL.
  • We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls.
  • Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls.
  • In every subclass except IgD, about 10-15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls.
  • Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels.
  • In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses.
  • In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types.
  • Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD80 / blood. Female. Humans. Immunoglobulin E / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235925.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


45. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr: Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst; 2006 Jul 5;98(13):936-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly increasing incidence of ocular non-hodgkin lymphoma.
  • A recent report suggesting that ocular adnexal non-Hodgkin lymphoma (NHL) may be related to Chlamydia psittaci infection underscores the need for reliable epidemiologic data for this malignancy.
  • During 1992-2001 in the 12 SEER areas, ocular (i.e., eye and adnexa) NHL rates per 100,000 person-years for both sexes were highest among Asians/Pacific Islanders, lower in whites, and lower still in blacks.
  • From 1975-2001, there was a rapid and steady increase in incidence of ocular NHL, with annual increases of 6.2% and 6.5% among white males and females, respectively, with no evidence of peaking.
  • The distinctive patterns of ocular NHL call for further studies to identify risk factors and mechanisms, including the potential role of C. psittaci or other infections.
  • [MeSH-major] Eye Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Chlamydophila psittaci. Female. Humans. Incidence. Lymphoma, B-Cell, Marginal Zone / epidemiology. Male. Middle Aged. Psittacosis / complications. Psittacosis / microbiology. SEER Program. Sex Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818858.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


46. Engels EA: Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):401-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious agents as causes of non-Hodgkin lymphoma.
  • Among exposures presently viewed as possible etiologic factors in non-Hodgkin lymphoma (NHL), infections are close to being regarded as established causes.
  • Infectious agents causing NHL can be classified, according to mechanism, into three broad groups.
  • Lymphocyte-transforming viruses include Epstein Barr virus (linked to Burkitt's lymphoma, NHLs in immunosuppressed individuals, and extranodal natural killer/T-cell NHL), human herpesvirus 8 (primary effusion lymphoma), and human T lymphotropic virus type I (adult T-cell leukemia/lymphoma).
  • Second, human immunodeficiency virus is unique in causing profound depletion of CD4+ T lymphocytes, leading to acquired immunodeficiency syndrome and an associated high risk for some NHL subtypes.
  • Third, recent evidence suggests that some infections increase NHL risk through chronic immune stimulation.
  • Establishing that an infectious agent causes NHL depends on showing that the agent is present in persons with NHL as well as laboratory experiments elucidating the mechanisms involved.
  • Only epidemiologic studies can provide evidence that infection is actually a risk factor by showing that infection is more frequent in NHL cases than in controls.
  • Given the range of mechanisms by which infections could plausibly cause NHL and our growing molecular understanding of this malignancy, this field of research deserves continued attention.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337646.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


47. Steiropoulos P, Kouliatsis G, Karpathiou G, Popidou M, Froudarakis ME: Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas. Respiration; 2009;77(4):459-63
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas.
  • Primary pleural lymphoma is rare.
  • It occurs in only 7% of lymphoma cases.
  • We report herein two cases of primary pleural Hodgkin and non-Hodgkin follicular lymphomas diagnosed by thoracoscopy under local anesthesia.
  • The pleural findings during thoracoscopy differed in the two cases and selective pleural biopsies under optical forceps led to the diagnosis of lymphoma.
  • To date, primary pleural Hodgkin and non-Hodgkin follicular lymphomas have not been reported.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Follicular / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Dyspnea / etiology. Female. Humans. Male. Middle Aged. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18503251.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


48. Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):126-31
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin lymphoma.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation.
  • Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of choice for stage IA NLPHL.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Recurrence. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425457.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


49. Centkowski P, Brydak L, Machała M, Kalinka-Warzocha E, Błasińska-Morawiec M, Federowicz I, Walewski J, Wegrzyn J, Wołowiec D, Lech-Marańda E, Sawczuk-Chabin J, Biliński P, Warzocha K, Polish Lymphoma Research Group: Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol; 2007 May;27(3):339-46
MedlinePlus Health Information. consumer health - Flu Shot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
  • PURPOSE: The purpose of this study was to assess humoral response to influenza vaccine in patients (pts) with non-Hodgkin lymphoma (NHL) as compared to healthy subjects (ctrl).
  • At 1 month after vaccination, seroprotection and seroresponse rates were similar in both groups, ranging from 68.42 to 84.21% and 71.93 to 94.74% in NHL, and 66.67-82.22% and 62.22-86.67% in ctrl, respectively.
  • CONCLUSIONS: The results indicate that influenza vaccination induces sufficient immune response in pts with NHL, irrespective of previous chemotherapy.
  • [MeSH-major] Influenza Vaccines / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies / blood. Antibodies / immunology. Female. Hemagglutinins / immunology. Humans. Influenza A virus / immunology. Influenza, Human / immunology. Influenza, Human / prevention & control. Male. Middle Aged. Neuraminidase / immunology. Neuraminidase / metabolism. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345151.001).
  • [ISSN] 0271-9142
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Hemagglutinins; 0 / Influenza Vaccines; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


50. Hartge P, Colt JS, Severson RK, Cerhan JR, Cozen W, Camann D, Zahm SH, Davis S: Residential herbicide use and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):934-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential herbicide use and risk of non-Hodgkin lymphoma.
  • CONTEXT: Environmental exposure to herbicides has been hypothesized to contribute to the long-term increase in non-Hodgkin lymphoma (NHL).
  • OBJECTIVE: To estimate the effects of residential herbicide exposure on NHL risk.
  • PARTICIPANTS: NHL patients ages 20 to 74 years and unaffected residents identified by random digit dialing and Medicare eligibility files.
  • Residential herbicide exposures are unlikely to explain the long-term increase in NHL.
  • [MeSH-major] Environmental Exposure / adverse effects. Herbicides / adverse effects. Lymphoma, Non-Hodgkin / chemically induced. Population Surveillance / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Dust / analysis. Female. Housing. Humans. Male. Middle Aged. Multicenter Studies as Topic. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824166.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dust; 0 / Herbicides
  • [Number-of-references] 22
  •  go-up   go-down


51. Paes FM, Kalkanis DG, Sideras PA, Serafini AN: FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics; 2010 Jan;30(1):269-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
  • Almost any organ can be affected by lymphoma, with the most common extranodal sites of involvement being the stomach, spleen, Waldeyer ring, central nervous system, lung, bone, and skin.
  • The prevalence of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease has increased in the past decade.
  • More recently, hybrid PET/CT has become the standard imaging modality for initial staging, follow-up, and treatment response assessment in patients with lymphoma and has proved superior to CT in these settings.
  • In addition, a knowledge of the differences in FDG avidity among the histologic subtypes of lymphoma, appropriate timing of scanning after therapeutic interventions, and use of techniques to prevent brown fat uptake are essential for providing the oncologist with accurate information.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Subtraction Technique. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083598.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Hjalgrim H, Seow A, Rostgaard K, Friborg J: Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer; 2008 Aug 1;123(3):716-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of Hodgkin lymphoma incidence in Singapore.
  • A bimodal age-specific incidence pattern with a relatively high proportion of cases occurring in adolescents and young adults is a hallmark of Hodgkin lymphoma (HL) epidemiology in Western industrialized countries.
  • The young adult incidence peak is believed to reflect the association between HL risk in young adults and an affluent childhood socioeconomic environment.
  • However, the dynamic development of the young adult incidence peak following socioeconomic development implied by this interpretation has scarcely been demonstrated in a single population over time.
  • It remains to be determined to what extent the current lower incidence of HL in young Asian adults should be attributed to birth cohort phenomena, as would be suggested by continued increase in incidence, and to ethnic variation in HL susceptibility between Asian and non-Asian populations, respectively.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Confidence Intervals. Female. Genetic Predisposition to Disease. Humans. Incidence. Infant. Male. Middle Aged. Poisson Distribution. Singapore / epidemiology. Socioeconomic Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470916.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. De Roos AJ, Davis S, Colt JS, Blair A, Airola M, Severson RK, Cozen W, Cerhan JR, Hartge P, Nuckols JR, Ward MH: Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma. Environ Res; 2010 Jan;110(1):70-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma.
  • Industrial pollution has been suspected as a cause of non-Hodgkin lymphoma (NHL), based on associations with chemical exposures in occupational studies.
  • We conducted a case-control study of NHL in four SEER regions of the United States, in which residential locations of 864 cases and 684 controls during the 10 years before recruitment were used to characterize proximity to industrial facilities reporting chemical releases to the Environmental Protection Agency's Toxics Release Inventory (TRI).
  • For each of 15 types of industry (by 2-digit SIC code), we evaluated the risk of NHL associated with having lived within 2 miles of a facility, the distance to the nearest facility (miles categories of < or =0.5, >0.5-1.0, >1.0-2.0, >2 [referent]), and the duration of residence within 2miles (years categories of 10, 1-9, 0 [referent]), using logistic regression.
  • Increased risk of NHL was observed in relation to lumber and wood products facilities (SIC 24) for the shortest distance of residential proximity (< or =0.5 mile: odds ratio [OR]=2.2, 95% confidence interval [CI]: 0.4-11.8) or the longest duration (10 years: OR=1.9, 95% CI: 0.8-4.8); the association with lumber facilities was more apparent for diffuse large B-cell lymphoma (lived within 2 miles: OR=1.7, 95% CI: 1.0-3.0) than for follicular lymphoma (OR=1.1, 95% CI: 0.5-2.2).
  • This study does not provide strong evidence that living near manufacturing industries increases NHL risk.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Epidemiology. 2003 Nov;14(6):687-93 [14569184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1981 Feb;25:49-197 [6939657.001]
  • [Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):542-7 [15951673.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Occup Environ Med. 2009 Jan;66(1):23-31 [18805886.001]
  • [Cites] BMC Public Health. 2009;9:26 [19159450.001]
  • (PMID = 19840879.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / R03 CA115183; United States / NCI NIH HHS / CA / CA115183-02; United States / NCI NIH HHS / CA / R03 CA115183-02; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R03CA115183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Industrial Waste
  • [Other-IDs] NLM/ NIHMS153621; NLM/ PMC2795078
  •  go-up   go-down


54. Engels EA, Rollison DE, Hartge P, Baris D, Cerhan JR, Severson RK, Cozen W, Davis S, Biggar RJ, Goedert JJ, Viscidi RP: Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer; 2005 Dec 20;117(6):1013-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma.
  • Because JCV can infect lymphocytes and cause chromosomal damage, it is a plausible candidate to cause non-Hodgkin lymphoma (NHL).
  • First, in a U.S. population-based case-control study of NHL (724 cases, 622 controls), we found lower JCV antibody levels in cases than controls (median optical density = 0.12 vs. 0.21, p < 0.0001); likewise, JCV seroprevalence was lower in cases (49% vs. 59%, adjusted odds ratio [OR] = 0.70, 95% confidence interval [CI] = 0.56-0.87).
  • Second, we found that JCV and BKV antibody levels changed little over time among 24 NHL patients receiving chemotherapy.
  • Antibody levels were much higher in shedders than non-shedders (JCV: median optical density = 0.67 vs. 0.07, p < 0.0001; BKV: 0.87 vs. 0.40, p = 0.003), indicating that these antibodies are a marker for viral replication.
  • Because no deficit of BKV antibody was seen in NHL cases, and because antibody levels did not change materially with chemotherapy, we suggest that the lower levels of JCV antibody observed in NHL patients may not be due entirely to a disease or treatment effect.
  • Additional research is needed to determine whether JCV replication is decreased in individuals with NHL and whether these findings are consistent with an etiologic role for JCV in NHL.
  • [MeSH-major] Antibodies, Viral / blood. BK Virus / immunology. JC Virus / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. DNA, Viral / urine. Female. HIV Infections / virology. Homosexuality. Humans. Immunoglobulin G / blood. Male. Middle Aged. National Institutes of Health (U.S.). Polymerase Chain Reaction. Registries. SEER Program. United States. Virus Replication. Virus Shedding

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986438.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin G
  •  go-up   go-down


55. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP: Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant; 2008 Apr;14(4):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
  • Allogeneic stem cell transplantation (SCT) with reduced-intensity conditioning (RIC) has the potential to lead to long-term remissions for patients with lymphoma.
  • However, the role of RIC SCT in the treatment of lymphoma is still unclear.
  • Specifically, the relative benefit of RIC SCT across lymphoma histologies and the prognostic factors in this population are incompletely defined.
  • We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan.
  • Thirty-six patients had Hodgkin disease (HD) and 51 had non-Hodgkin lymphoma (NHL).
  • Three-year overall survival (OS) was 56% for patients with HD, 81% for indolent NHL, 42% for aggressive NHL, and 40% for mantle cell lymphoma.
  • Multivariate analysis identified elevated pretransplantation lactate dehydrogenase (LDH) as an adverse factor for PFS, while indolent NHL histology was favorable.
  • For OS, advanced age and elevated pretransplantation LDH were adverse factors, whereas indolent NHL histology was favorable.
  • These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2342-50 [8246023.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1291-6 [8648386.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):655-61 [16007106.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):235-44 [16513231.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 [17084369.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4314-21 [11731514.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • (PMID = 18342784.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NHLBI NIH HHS / HL / HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NHLBI NIH HHS / HL / HL070149-05; United States / NHLBI NIH HHS / HL / P01 HL070149-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS43829; NLM/ PMC2364453
  •  go-up   go-down


56. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, Davis S, Severson RK, Rothman N, Chanock SJ, Hartge P: Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res; 2007 May 15;67(10):5042-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.
  • Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non-Hodgkin lymphoma (NHL) in a large pooled analysis.
  • We systematically investigated the effects of other established NHL risk factors in relation to the tumor necrosis factor (TNF) G308A or interleukin 10 (IL10) T3575A genotypes.
  • We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma].
  • NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (OR(NHL), 2.1; 95% CI, 1.0-4.2) or the IL10 T3575A TA/AA genotype (OR(NHL), 1.6; 95% CI, 0.9-2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Interleukin-10 / genetics. Interleukin-10 / immunology. Male. Middle Aged. Polymorphism, Single Nucleotide. Risk Factors. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510437.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


57. Claviez A, Meyer U, Dominick C, Beck JF, Rister M, Tiemann M: MALT lymphoma in children: a report from the NHL-BFM Study Group. Pediatr Blood Cancer; 2006 Aug;47(2):210-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT lymphoma in children: a report from the NHL-BFM Study Group.
  • Marginal zone lymphomas of MALT type comprise a considerable group of indolent B-cell non-Hodgkin lymphoma (NHL) in adult patients.
  • In childhood, however, these tumors are extremely rare, as nearly all pediatric patients have aggressive NHL.
  • Among 2,703 children and adolescents registered into the prospective multicenter NHL-BFM treatment studies since 1986, only 4 patients (0.1%) displayed features of MALT lymphoma.
  • All children are alive but long-term follow-up will be mandatory to assess the behavior of MALT lymphoma in this age group.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123999.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Bartlett NL: Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program; 2005;:245-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
  • Autologous stem cell transplant remains the standard of care for relapsed Hodgkin lymphoma (HL).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304388.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


59. Darby S, Hancock BW: Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience. Int J Oncol; 2005 Apr;26(4):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience.
  • We evaluated clinical features, management and survival of patients with localised (stage 1E or 2E) testicular non-Hodgkin lymphoma (NHL) presenting to the Sheffield Lymphoma Group between 1972 and 2002.
  • Thirty consecutive eligible patients were identified from the lymphoma database and clinical records of all were reviewed.
  • Six (20%) died of causes not related to their lymphoma.
  • Primary testicular lymphoma is an uncommon and poor prognosis disease usually affecting older men.
  • The data and experience available to guide the treatment strategies for testicular lymphoma are limited.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Neoplasm Recurrence, Local. Orchiectomy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies


60. Abid MB, Nasim F, Anwar K, Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev; 2005 Oct-Dec;6(4):531-4
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic?
  • There has been a recent concern among oncological clinicians and pathologists of our region regarding the disproportionate increase in the number of patients presenting with diffuse large B cell lymphoma (DLBCL).
  • A total of 780 specimens were collected over last half decade from cases classified as adult Non Hodgkin's lymphoma (NHL).
  • Nodal-NHLs constituted 42.2 % of all adult NHLs, with the cervical lymph nodes as the most frequent nodal site of presentation.
  • [MeSH-major] Disease Outbreaks. Lymphoma, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436006.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


61. Tavani A, Bosetti C, Franceschi S, Talamini R, Negri E, La Vecchia C: Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma. Eur J Cancer Prev; 2006 Oct;15(5):453-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma.
  • Individuals diagnosed with skin cancer have elevated risk of non-Hodgkin lymphoma, and those with non-Hodgkin lymphoma have excess rates of various types of skin cancers.
  • Sunshine and other sources of ultraviolet radiation are major risk factors for skin cancer, and hence a potential common link between skin cancer and non-Hodgkin lymphoma.
  • We analyzed the relationship between occupational exposure to ultraviolet radiation and the risk for non-Hodgkin lymphoma using data from a case-control study conducted in Northern Italy between 1985 and 1997.
  • Cases were 446 patients with histologically confirmed incident non-Hodgkin lymphoma, and controls were 1295 patients admitted to hospital for acute non-neoplastic, non-immunological conditions.
  • Our study found no association between occupational exposure to ultraviolet radiation and the risk of non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Occupational Exposure. Ultraviolet Rays
  • [MeSH-minor] Adult. Case-Control Studies. Confidence Intervals. Female. Humans. Male. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912575.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • [Transliterated title] Linfomas no Hodgkin en patología cérvico-facial.
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • CONCLUSION: There is an evident relationship between NHL and the Oto-Rhino-laringology area and it is necessary consider it in the differential diagnosis of head and neck adenopathies.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


63. Jacobs BL, Blodgett TM, Monaco SE, Hrebinko RL, Jacobs SA: Adrenal insufficiency as presenting feature of non-Hodgkin lymphoma. Can J Urol; 2010 Oct;17(5):5411-4
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal insufficiency as presenting feature of non-Hodgkin lymphoma.
  • Lymphomatous involvement of an adrenal gland during the course of a lymphoma is common, but a primary presentation of adrenal insufficiency in a patient with lymphoma involving both adrenal glands is rare.
  • We describe a 36-year-old man with non-Hodgkin lymphoma (NHL) who presented with adrenal insufficiency.
  • Our case illustrates the importance of preoperative evaluation to exclude a lymphoma, particularly in patients with bilateral renal and/or adrenal masses.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Insufficiency / etiology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2010 Oct;17(5):5414 [20974042.001]
  • (PMID = 20974041.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


64. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L: Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev; 2006;30(1):99-101
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs.
  • BACKGROUND: Risk factors for non-Hodgkin lymphoma (NHL) are largely unknown.
  • Several studies have examined the relation of non-steroidal anti-inflammatory drug (NSAID) use to the risk of NHL, with inconsistent results.
  • METHODS: We examined NSAID use among 529 newly diagnosed NHL cases and 2013 controls interviewed from 1977 to 2002 in our Case-Control Surveillance Study.
  • RESULTS: The odds ratio for NHL among subjects whose regular NSAID use began at least one year prior to hospital admission compared to never users was 0.9 (95% confidence interval (CI): 0.6-1.3).
  • CONCLUSION: Our results add to the body of data suggesting that NSAIDs do not increase the risk of NHL and even suggest the possibility of protection by long-term use.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Lymphoma, Non-Hodgkin / chemically induced
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Odds Ratio. Population Surveillance. Prognosis. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495019.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA45762; United States / FDA HHS / FD / FD-U-00082
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


65. Karipidis KK, Benke G, Sim MR, Kauppinen T, Kricker A, Hughes AM, Grulich AE, Vajdic CM, Kaldor J, Armstrong B, Fritschi L: Occupational exposure to ionizing and non-ionizing radiation and risk of non-Hodgkin lymphoma. Int Arch Occup Environ Health; 2007 Aug;80(8):663-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to ionizing and non-ionizing radiation and risk of non-Hodgkin lymphoma.
  • OBJECTIVE: To investigate the association between occupational exposure to ionizing, ultraviolet (UV), radiofrequency (RF) and extremely low frequency (ELF) radiation and risk of developing non-Hodgkin lymphoma (NHL) in a population-based case-control study.
  • METHODS: The study population consisted of 694 NHL cases, first diagnosed between 1 January 2000 and 31 August 2001, and 694 controls from two regions in Australia, matched by age, sex and region of residence.
  • CONCLUSIONS: Our results do not provide support for an association between NHL and occupational exposure to ionizing or ELF radiation.
  • Further investigation focusing on UV and RF radiation and NHL is required.
  • [MeSH-major] Dose-Response Relationship, Radiation. Lymphoma, Non-Hodgkin / etiology. Neoplasms, Radiation-Induced / etiology. Occupational Exposure / adverse effects
  • [MeSH-minor] Adult. Aged. Australian Capital Territory / epidemiology. Case-Control Studies. Humans. Interviews as Topic. Logistic Models. Middle Aged. New South Wales / epidemiology. Odds Ratio. Radiation, Ionizing. Radio Waves / adverse effects. Risk Factors. Ultraviolet Rays / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334774.001).
  • [ISSN] 0340-0131
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


66. Grubstein A, Givon-Madhala O, Morgenstern S, Cohen M: Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis. J Clin Ultrasound; 2005 Mar-Apr;33(3):140-2
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.
  • We report a case of primary, high-grade non-Hodgkin B-cell lymphoma in the breast of a young woman.
  • Primary breast lymphoma is a rare entity, especially in young females.
  • In previous imaging reports of breast lymphoma, it has always been considered as a mass, though the presence of markedly hypoechoic regions that look like fluid collections is a well known sonographic characteristic of lymphoma.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography. Mastitis / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Mammary


67. Ho L, Valenzuela D, Negahban A, Wassef H: Primary spinal epidural non-Hodgkin lymphoma demonstrated by FDG PET/CT. Clin Nucl Med; 2010 Jul;35(7):487-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary spinal epidural non-Hodgkin lymphoma demonstrated by FDG PET/CT.
  • We report the F-18 fluorodeoxyglucose positron emission tomography/computed tomography appearance of a biopsy-proven primary epidural non-Hodgkin lymphoma involving the lower cervical and upper thoracic spine with a small hypermetabolic right middle lobe nodule in a 33-year-old man.
  • Primary spinal epidural non-Hodgkin lymphoma is a rare form of malignancy, constituting approximately 0.1% to 3.3% of all lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Spinal Cord Neoplasms / radiography. Spinal Cord Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20548138.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


68. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer; 2005 Nov;45(6):753-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
  • Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma.
  • With systematic improvements in therapy over recent decades, the vast majority of children with NHL of all subtypes are now cured.
  • The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15929129.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA13697; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 157
  •  go-up   go-down


69. Otrock ZK, Shamseddine AI, Taher AT: Non-Hodgkin disease in beta-thalassemia major. Am J Hematol; 2006 Jan;81(1):62-4
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin disease in beta-thalassemia major.
  • The occurrence of lymphoma in thalassemia has rarely been reported, and our review of the English literature revealed only four cases.
  • We hereby report the case of a thalassemic patient developing non-Hodgkin disease and discuss the possibility of a link between the two disease entities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. beta-Thalassemia
  • [MeSH-minor] Adult. Child. Child, Preschool. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Female. Humans. Infant. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thalassemia.
  • Genetic Alliance. consumer health - Beta Thalassemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16369971.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCOP protocol
  •  go-up   go-down


70. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK: Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis; 2007 Mar;28(3):704-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study.
  • Recent findings suggest that genetic polymorphisms in TNF and IL10 are associated with an increased risk of non-Hodgkin lymphoma (NHL), particularly for diffuse large B-cell lymphoma (DLBCL).
  • To further investigate the contribution of common genetic variation in key cytokine and innate immunity genes to the etiology of NHL, we genotyped participants in a case-control study of NHL conducted in Australia (545 cases, 498 controls).
  • Our most noteworthy TNF finding was an association between -857C>T and a decreased risk of NHL (CT or TT, OR=0.59, 95% CI=0.42-0.84, P=0.003) and particularly follicular lymphoma (OR=0.40, 95% CI=0.23-0.68, P=0.0009).
  • Our findings offer further evidence that variation in the IL10 and TNF loci influences NHL risk.
  • [MeSH-major] Interleukins / genetics. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Chromosome Mapping. Female. Humans. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / immunology. Lymphotoxin-alpha / genetics. Male. Middle Aged. New South Wales / epidemiology. Polymorphism, Single Nucleotide. Receptors, Cell Surface / genetics. Receptors, Leptin. Registries. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056605.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukins; 0 / Lymphotoxin-alpha; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


71. Kumar R, Xiu Y, Dhurairaj T, Yu JQ, Alavi A, Zhuang H: F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med; 2005 Apr;30(4):246-8
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast.
  • The breast is an uncommon site of development of extranodal non-Hodgkin lymphoma (NHL).
  • A 36-year-old woman diagnosed with NHL underwent multimodality imaging for staging of the disease.
  • Cytologic examination confirmed breast involvement by diffuse large B-cell NHL.
  • Although rare, breast involvement characterized by increased FDG uptake can occur in patients with lymphoma.
  • This case highlights the role of FDG PET in patients with suspected lymphoma in dense breasts that can be missed by CT scan and mammogram.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma, B-Cell / radionuclide imaging. Positron-Emission Tomography / methods. Rare Diseases / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764881.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Yang F, Shi JY, Xu L, Ren LJ, Zhang QH, Zhao WL, Shen ZX: [Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2009 Sep;30(9):622-5
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma].
  • OBJECTIVE: To evaluate the relationship between five single nucleotide polymorphism loci in the MGMT, XPA, XPD and XPG genes and the prevalence of non-Hodgkin's lymphoma.
  • METHODS: A case-control study of 73 lymphoma cases and 500 healthy controls was conducted and the Mass-ARRAY method was applied for detection of MGMT L84F, MGMT K178R, XPA TSS+62, XPD K751Q and XPG TSS+372.
  • RESULTS: MGMT L84F (T allele) was associated with an increased risk of non-Hodgkin lymphoma (OR=2.085, 95%CI=1.069-4.068, P=0.029), mainly in B-cell lymphoma, of which the risk increased by 2.403-fold (OR=2.403, 95%CI=1.103-5.235, P=0.024).
  • CONCLUSION: Single nucleotide polymorphism in the MGMT gene may closely related to the occurrence of non-Hodgkin lymphoma, especially of B-cell subtype.
  • [MeSH-major] DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954624.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


73. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, FHDH ANRS CO4 ANRS CO141: Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr; 2009 Feb 1;50(2):206-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
  • Here we compared the risks of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in IL-2-treated and IL-2-untreated HIV-infected patients.
  • Poisson regression models were used in 2 separate analyses to quantify the possible relationship between IL-2 therapy and the incidence of NHL and HL.
  • After adjustment for sex and time-updated age, period, the CD4 cell counts, the plasma HIV RNA levels, and AIDS status, the relative rates of NHL and HL associated with IL-2 therapy were 0.64 (95% confidence interval, 0.25 to 1.65) and 0.33 (95% confidence interval, 0.04 to 2.86), respectively.
  • CONCLUSIONS: In this large observational study, IL-2 therapy did not increase the risk of lymphoma, either NHL or HL, in HIV-infected patients.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / epidemiology. Interleukin-1 / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Female. France. Hospitals. Humans. Incidence. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131886.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong M; Lang JM; Lascaux A; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard J; Pavie J; Pialoux G; Pilorgé F; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard J; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Abgrall S; Grabar S; Guiguet M; Lanoy E; Lièvre L; Mary-Krause M; Potard V; Selinger-Leneman H; Fichou J; Bouvet E; Crickx B; Ecobichon J; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Salmon D; Sicard D; Auperin I; Gilquin J; Roudière L; Viard J; Boué F; Fior R; Delfraissy J; Goujard C; Jung C; Lesprit P; Desplanque N; Meynard JL; Meyohas M; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel J; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine J; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont J; Moreau J; Gastaut J; Retornaz F; Soubeyrand J; Allegre T; Blanc P; Galinier A; Ruiz J; Lepeu G; Granet-Brunello P; Esterni J; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang J; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand M; Yazdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M; Lévy Y; Aboulker J; Bursachi P; Delfraissy J; Saïdi Y; Lascaux A; Saïdi S; Commoy M; Chêne G; Viard JP; Molina J; Tubiana R; Lascaux AS; Berdah M; Jung C; Molina J; Lafaurie M; Schnell-Niedbalski L; Oksenhendler E; Gérard L; Delfraissy J; Goujard C; Chaix F; Rannou MT; Tegna L; Tisne-Dessus D; Jeanblanc F; Beck-Wirth G; Benomar M; Verdon R; Bazin C; Goubin P; Girard P; Boudraa C; Sebire M; Viard J; Maignan A; Tubiana R; Katlama C; Curjol A; Fabre G; Trepo C; Brochier C; Thoirain V; Bloch M; Mortier E; Dupon M; Raymond I; Ragnaud JM; Raymond I; Sellier P; Magnier JD; Simon A; Iguerstira M; Gastaut J; Dalmas AM; Aboulker J; Guéguen S; Circosta S; Mourlhou P; Saouzanet-Harel M; Izard S; Saïdi Y
  •  go-up   go-down


74. Herbertson RA, Evans LS, Hutchinson J, Horsman J, Hancock BW: Poor outcome in adolescents with high-risk Hodgkin lymphoma. Int J Oncol; 2008 Jul;33(1):145-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome in adolescents with high-risk Hodgkin lymphoma.
  • This retrospective study looks at the differences between adolescents (15-19 years) and young adults (20-25 years), diagnosed with Hodgkin lymphoma and treated at the same adult institution.
  • There was no difference in the documented number of delays, dose reductions or episodes of non-compliance during initial treatment in the two high-risk age groups.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Humans. Retrospective Studies. Risk

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575760.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


75. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB: Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control; 2005 Apr;16(3):301-8
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma.
  • Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of non-Hodgkin lymphoma (NHL), although previous results have been inconsistent.
  • The current study investigated the effects of regular aspirin or acetaminophen use on non-Hodgkin lymphoma risk among 625 individuals with primary, incident NHL and 2512 age and sex matched hospital controls with non-neoplastic conditions who completed a comprehensive epidemiologic questionnaire.
  • Results indicate that regular aspirin use may be associated with decreased NHL risk among men [adjusted odds ratio (aOR) 0.82, 95% confidence interval (CI), 0.65--1.04], but not among women (aOR 0.93, 95% CI, 0.71--1.23).
  • In contrast, regular acetaminophen use was associated with elevated NHL risk among women (aOR 1.71, 95% CI, 1.18--2.50) but not among men (aOR 0.75, 95% CI, 0.48--1.17).
  • Other studies have demonstrated that acetaminophen is associated with transient decreases in DNA repair, and lymphocytes may be particularly susceptible to DNA damage, suggesting a mechanism for the elevated NHL risk observed.
  • [MeSH-major] Acetaminophen / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / prevention & control
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA Damage. DNA Repair. Female. Humans. Incidence. Lymphocytes. Male. Middle Aged. Odds Ratio. Sex Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947882.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 362O9ITL9D / Acetaminophen; R16CO5Y76E / Aspirin
  •  go-up   go-down


76. Gurol Y, Kipritci Z, Selcuk NA, Koc Y, Kocagoz S: Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report. Prague Med Rep; 2008;109(1):19-22
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report.
  • A case report is presented concerning Bacillus circulans paracardiac infection in a 27 year old woman with non-hodgkin lymphoma.
  • [MeSH-major] Bacillaceae Infections / diagnosis. Immunocompromised Host. Lymphoma, Non-Hodgkin / microbiology. Mediastinal Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097386.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


77. Kim HN, Yu L, Kim NY, Lee IK, Kim YK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, Kim HJ: Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol; 2010 Oct;85(10):822-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma.
  • Few studies have investigated its role in the susceptibility to non-Hodgkin lymphoma (NHL) [5,6].
  • To examine the association between this polymorphism and NHL risk, we conducted a Korean large-scale, population-based case-control study (945 cases and 1,700 controls).
  • The TP53 72CC genotype was associated with increased risk of NHL (P 5 0.04) and diffuse large B-cell lymphoma (P 5 0.04).
  • Our findings provide evidence that the TP53 Arg72Pro is associated with an increased risk of NHL in Korea.
  • [MeSH-major] Genes, p53. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Codon / genetics. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Republic of Korea / epidemiology. Risk. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734458.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


78. Brydak LB, Machała M, Centkowski P, Warzocha K, Biliński P: Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine; 2006 Nov 10;24(44-46):6620-3
MedlinePlus Health Information. consumer health - Flu Shot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma.
  • Lymphoma disease and immunosuppressive drugs used in this case cause immunity disorders increasing the risk of severe infections, including influenza.
  • The aim was to assess humoral response to influenza vaccine in 32 patients with non-Hodgkin malignant lymphoma (mean age 57.2) and 32 healthy subjects (mean age 44.3).
  • This study showed that influenza vaccine is less immunogenic in patients with non-Hodgkin malignant lymphoma, because it induces antibody production in lower titers in comparison to the production in healthy people.
  • [MeSH-major] Antibodies, Viral / biosynthesis. Antibody Formation / immunology. Influenza Vaccines / immunology. Lymphoma, B-Cell / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemagglutinin Glycoproteins, Influenza Virus. Humans. Immunity, Active / drug effects. Immunity, Active / immunology. Influenza, Human / immunology. Influenza, Human / prevention & control. Male. Middle Aged. Vaccination

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870313.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Hemagglutinin Glycoproteins, Influenza Virus; 0 / Influenza Vaccines
  •  go-up   go-down


79. Radić-Kristo D, Planinc-Peraica A, Ostojić S, Vrhovac R, Kardum-Skelin I, Jaksić B: Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics. Coll Antropol; 2010 Jun;34(2):413-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics.
  • Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas with an increasing incidence.
  • The incidence, clinicopathologic characteristics, treatment and survival were assessed in 39 successive, newly diagnosed PGI-NHL patients (23 male and 16 female) treated at "Merkur" University Hospital.
  • The most common site of PGI-NHL was stomach (n = 29, 74%), followed by small intestine (n = 5, 13%), and colon and rectosigmoid (n = 5, 13%).
  • According to World Health Organization (WHO) classification, 29 (87%) patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal zone B-cell lymphoma-mucosa associated tissue (MALT).
  • Patients with localized lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years.
  • In conclusion, our patient group was comparable to other literature reports on PGI-NHL patients according to clinicopathologic characteristics.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / epidemiology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Female. Humans. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Rectal Neoplasms / epidemiology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Retrospective Studies. Sigmoid Neoplasms / epidemiology. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Survival Rate. Young Adult


80. Kako S, Oshima K, Sato M, Terasako K, Okuda S, Nakasone H, Yamazaki R, Tanaka Y, Tanihara A, Kawamura Y, Kiyosaki H, Higuchi T, Nishida J, Konishi F, Kanda Y: Clinical outcome in patients with small-intestinal non-Hodgkin lymphoma. Leuk Lymphoma; 2009 Oct;50(10):1618-24
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome in patients with small-intestinal non-Hodgkin lymphoma.
  • The clinical features and outcome of small intestinal lymphoma remain unclear.
  • We retrospectively analyzed 23 patients who had non-Hodgkin lymphoma with a small intestinal lesion.
  • Perforation often resulted in a dismal prognosis in patients with uncontrollable lymphoma, but not in patients with lymphoma in remission.
  • The role of surgery in small intestinal lymphoma remains equivocal.
  • [MeSH-major] Ileal Neoplasms / mortality. Jejunal Neoplasms / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / etiology. Humans. Intestinal Obstruction / etiology. Intestinal Perforation / etiology. Japan / epidemiology. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672778.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Wilop S, Galm O, Dada R, Osieka R, Jost E: Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leuk Lymphoma; 2008 Nov;49(11):2116-24
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma.
  • We have analysed retrospectively the change of platelet counts following the administration of rituximab in 253 patients with non-Hodgkin lymphoma (NHL).
  • The risk factors to develop a decline in platelets after infusion of rituximab were pre-existent thrombocytopenia, advanced lymphoma stage, bone marrow infiltration, splenomegaly, leukemic presentation, and Burkitt lymphoma histology.
  • In conclusion, a decline in platelet count after administration of rituximab was observed in patients with NHL, mainly those with pre-existing thrombocytopenia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Blood Platelets / drug effects. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Bone Marrow Diseases. Burkitt Lymphoma. Drug Therapy, Combination. Female. Humans. Leukemia. Male. Middle Aged. Platelet Count. Retrospective Studies. Risk Factors. Rituximab. Splenomegaly. Thrombocytopenia. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Nov;49(11):2035-6 [19021044.001]
  • (PMID = 19021054.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


82. Terschüren C, Gierer S, Brillant C, Paulus U, Löffler M, Hoffmann W: Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol; 2010 Oct;21(10):2045-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?
  • BACKGROUND: Improvement of lymphoma therapy is largely driven by clinical therapy optimization protocols (TOPs).
  • The study included patients with Hodgkin lymphoma (HL) and high-grade non-Hodgkin lymphoma (hgNHL).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423912.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Cvetković Z, Vucić V, Cvetković B, Petrović M, Ristić-Medić D, Tepsić J, Glibetić M: Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol; 2010 Aug;89(8):775-82
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma.
  • The data about the fatty acid (FA) status of non-Hodgkin lymphoma (NHL) patients are poor.
  • Therefore, the aim of this study was to investigate the FA profile of serum phospholipids in NHL patients related to the aggressiveness and clinical stage of NHL.
  • We analyzed the FA profile of serum phospholipids in 47 newly diagnosed, untreated NHL patients and in 29 healthy subjects.
  • Significantly higher (p < 0.001) levels of palmitic (16:0), oleic (18:1 n-9) and arachidonic acids (20:4 n-6), saturated and monounsaturated FA were found in NHL patients, while linoleic acid (18:2 n-6) and the levels of total polyunsaturated FA (PUFA), n-3 PUFA, eicosapentaenoic (20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3) were significantly reduced (p < 0.01).
  • The level of oleic acid in patients with indolent NHL was significantly lower (p < 0.05) than in more aggressive types of disease.
  • Contents of palmitoleic acid, docosatetraenoic (22:4 n-6), and PUFA was lower in very aggressive NHL.
  • Our results showed an abnormal FA profile in serum phospholipids in NHL patients.
  • [MeSH-major] Fatty Acids / blood. Lymphoma, Non-Hodgkin / blood. Phospholipids / blood
  • [MeSH-minor] Adult. Aged. Diet. Female. Humans. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20127484.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Phospholipids
  •  go-up   go-down


84. Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF: Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer; 2005 Sep 10;116(4):646-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma.
  • Somatic inactivation of NFKBIA, the gene encoding IkappaBalpha, is a frequent occurrence in the malignant Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL).
  • [MeSH-major] Genetic Predisposition to Disease. Germ-Line Mutation. Hodgkin Disease / genetics. I-kappa B Proteins / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. DNA Mutational Analysis. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Molecular Sequence Data. Pedigree. Polymorphism, Genetic. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15858823.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins
  •  go-up   go-down


85. Aref S, Mossad Y, El-Khodary T, Awad M, El-Shahat E: Cyclin Dl expression in B-cell non Hodgkin lymphoma. Hematology; 2006 Oct;11(5):365-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin Dl expression in B-cell non Hodgkin lymphoma.
  • Over-expression of cyclin D1 protein has been reported in several solid tumors and certain lymphoid malignancies, but little is known about the effect of its expression on clinical behavior and outcome in B-cell Non-Hodgkin lymphoma (NHL).
  • In this study, we investigated the expression of cyclin Dl in group of patients with NHL and correlated the results with the clinical and laboratory data.
  • The degree of expression of cyclin Dl protein was evaluated by flow cytometry in a group of NHL patients (n = 46) and in normal control group (n = 10).
  • Cyclin Dl over expression was detected in 10 out of 46 (21.7%) patients; they were 5/5-mantle cell lymphoma (MCL) (100%) and 5/28 large B-cell lymphoma (17.8%).
  • All other NHL subtypes showed normal cyclin D1 expression.
  • The clinical signs (hepatomegaly, splenomegaly and B-symptoms, clinical staging) and laboratory data (hemoglobin, white cell count (WBCs), platelet count, and bone marrow infiltration) were not significantly different between NHL subgroup with cyclin Dl over expression and that with normal cyclin Dl expression.
  • Serum lactic dehydrogenase (LDH) levels and lymphadenopathy were significantly higher in NHL group with cyclin D1 over expression as compared to those without.
  • Also, cyclin D1 over expression is associated with poor outcome of NHL patients.
  • Cyclin Dl over expression was evident among all cases of MCL and few cases of large B-cell lymphoma.
  • Cyclin Dl over expression might be used as adjuvant tool for diagnosis of MCL; has role in NHL biology and is bad prognostic index in NHL.
  • [MeSH-major] Cyclin D1 / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lymphatic Diseases. Male. Middle Aged. Prognosis. Up-Regulation


86. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC: Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol; 2010 Dec;28(4):168-79
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preservation after chemotherapy for Hodgkin lymphoma.
  • Treatment for Hodgkin lymphoma can negatively affect fertility.
  • This review summarizes data on fertility after chemotherapy in adult patients.
  • Non-alkylating chemotherapy, like ABVD, is much less harmful: one-third of male patients develop transient azoospermia, and almost no female patients experience ovarian failure.
  • For females with a partner, IVF followed by embryo cryopreservation is a widely available method, but this necessitates postponement of lymphoma therapy for at least a month.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Azoospermia / chemically induced. Cryopreservation / methods. Female. Humans. Male. Ovarian Diseases / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [CommentIn] Hematol Oncol. 2011 Mar;29(1):52; author reply 53 [20535782.001]
  • (PMID = 20232475.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


87. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R: FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet; 2008 May;183(1):35-40
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
  • Combined with chemotherapy or alone, in maintenance/consolidation, it is used for the treatment of non-Hodgkin lymphoma (NHL).
  • The role of a polymorphism in a specific Fc gamma receptor gene, FcgammaRIIa, in the clinical outcome of patients with NHL was investigated in this study.
  • We characterized DNA samples from 64 non-Hodgkin lymphoma patients treated with rituximab using a polymerase chain reaction-restriction fragment length polymorphism method.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / genetics. Drug Resistance, Neoplasm / genetics. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide. Receptors, IgG / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Female. Gene Frequency. Humans. Male. Middle Aged. Pharmacogenetics. Prognosis. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474295.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Fc gamma receptor IIA; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


88. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO: Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park); 2005 Feb;19(2):213-28; discussion 228, 233-6, 239
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: expanding therapeutic options.
  • The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide.
  • Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time.
  • Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation.
  • Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770890.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oligonucleotides, Antisense; 0 / Proteasome Inhibitors
  • [Number-of-references] 148
  •  go-up   go-down


89. Kaleem Z, McGuire MH, Caracioni AC, Leonard RL, Pathan MH, Lessmann EA, Chan WC: Composite B-cell and T-cell non-Hodgkin lymphoma of the tibia. Am J Clin Pathol; 2005 Feb;123(2):215-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite B-cell and T-cell non-Hodgkin lymphoma of the tibia.
  • We report a unique case of de novo composite lymphoma in the tibia of a 35-year-old man who presented with increasingly frequent and intense pain in the right upper leg.
  • Flow cytometry and immunohistochemical analysis showed composite lymphoma: diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell non-Hodgkin lymphoma with predominantly small cell morphologic features.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Multiple Primary / pathology. Tibia / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Clone Cells. Flow Cytometry. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunoglobulin kappa-Chains / analysis. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842045.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


90. Broderick P, Cunningham D, Vijayakrishnan J, Cooke R, Ashworth A, Swerdlow A, Houlston R: IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol; 2010 Feb;148(3):413-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.
  • The reciprocal familial risk between chronic lymphocytic leukaemia (CLL) and Hodgkin lymphoma (HL) suggests genetic variants with pleiotropic effects may influence the risk of both CLL and HL.
  • [MeSH-major] Hodgkin Disease / genetics. Interferon Regulatory Factors / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Assessment / methods. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804451.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / interferon regulatory factor-4
  •  go-up   go-down


91. Skibola CF, Lightfoot T, Agana L, Smith A, Rollinson S, Kao A, Adamson P, Morgan GJ, Smith MT, Roman E: Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma. Br J Haematol; 2005 Jun;129(5):618-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma.
  • Estrogen receptor expression in lymphocytes suggests that hormonal modulation may influence lymphoma risk.
  • CYP17A1-34T>C and CYP17A1 IVS2 105A>C polymorphisms were analyzed in a non-Hodgkin lymphoma (NHL) population-based case-control study.
  • The CYP17A1-34CC genotype was positively associated with NHL [odds ratio (OR) = 1.44, 95% confidence interval (CI) 1.02-2.03], particularly diffuse large B-cell lymphoma (OR = 1.76, CI 1.14-2.71).
  • Associations of CYP17A1 polymorphisms with increased risk of NHL suggest a role for oestrogen in lymphomagenesis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic. Steroid 17-alpha-Hydroxylase / genetics
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Confidence Intervals. Female. Genetic Predisposition to Disease. Humans. Lymphoma, B-Cell / genetics. Male. Middle Aged. Odds Ratio. Risk

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916684.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01-CA104862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.19 / CYP17A1 protein, human; EC 1.14.14.19 / Steroid 17-alpha-Hydroxylase
  •  go-up   go-down


92. Wang SS, Cozen W, Severson RK, Hartge P, Cerhan JR, Davis S, Welch R, Rothman N, Chanock SJ: Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet; 2006 Sep;120(2):297-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 splice variant and risk for non-Hodgkin lymphoma.
  • To investigate the role of cell cycle gene variations in lymphomagenesis, we evaluated associations (odds ratios [OR] and 95% confidence intervals [CI]) in polymorphisms from seven candidate genes in 1,172 non-Hodgkin lymphoma (NHL) cases and 982 population-based controls.
  • The cyclin D1 (CCND1) splice variant G870A (rs603965) increased NHL risk (OR(AA) = 1.4, 95% CI = 1.1-1.8, P-trend = 0.021), which was consistent for four B-cell subtypes.
  • As CCND1 expression indicates poor NHL prognosis, our results, if true, would support its potentially dual importance in NHL etiology and survival.
  • [MeSH-major] Alternative Splicing. Genes, bcl-1. Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Humans. Middle Aged. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783567.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N02-PC-71105
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  •  go-up   go-down


93. Au WY, Gascoyne RD, Klasa RD, Connors JM, Gallagher RP, Le ND, Loong F, Law CK, Liang R: Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol; 2005 Mar;128(6):792-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia.
  • The incidence and spectrum of non-Hodgkin lymphoma (NHL) differ between the Chinese and Caucasian populations.
  • Using population-based registries, we studied the pattern of NHL in Chinese migrants to British Columbia (BC).
  • The records of all NHL cases of Chinese descent diagnosed between 1980 and 1997 were retrieved.
  • The histological distribution of NHL was compared with 4500 consecutive NHL cases diagnosed in the two populations.
  • A total of 211 cases of migrant NHL were identified, with an age-standardized incidence rate of 7.11 per 100 000 per year, compared with the Hong Kong and BC rates of 7.91 [standardized incidence ratio (SIR) = 0.86, P = 0.01] and 11.88 (SIR = 0.56, P < 0.01).
  • The standardized rates of follicular lymphoma remained low, but the incidence of gastric and nasal natural killer/T lymphomas in migrants were lower than expected.
  • Genetic factors appeared to be stronger than environmental factors in governing the overall incidence of NHL in Chinese.
  • However, certain subtypes of lymphoma may show decreased rates in migrants because of environmental factors.
  • [MeSH-major] Lymphoma, Non-Hodgkin / ethnology. Transients and Migrants / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Asian Continental Ancestry Group / ethnology. British Columbia / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Infant. Male. Middle Aged. Poisson Distribution

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755282.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Bahl S, Theis B, Nishri D, Marrett LD: Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control; 2008 Dec;19(10):1251-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada.
  • OBJECTIVE: To examine the influence of the AIDS epidemic on the incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) in Ontario.
  • METHODS: Age-standardized incidence rates for KS and NHL from 1981 to 2000 were calculated from the population-based Ontario Cancer Registry.
  • NHL incidence in males increased steadily during the 1980s at 3.2% per year and then slowed beyond 1990.
  • In males aged 30-44, NHL incidence rose from 1981 to 1990 (8.8% per year) and then fell (-2.5%) thereafter.
  • NHL and KS cases represented one-third of HIV deaths.
  • NHL incidence trends are more complex, although the AIDS epidemic explains the trends observed in younger men (in whom AIDS is more common), and for the AIDS-related subtypes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Population Surveillance. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Adult. Burkitt Lymphoma / epidemiology. Humans. Incidence. Logistic Models. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large-Cell, Immunoblastic / epidemiology. Male. Ontario / epidemiology. Registries / statistics & numerical data. Retrospective Studies


95. Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, Chanock S: Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet; 2007 Apr;121(2):161-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.
  • In a population-based case-control study of non-Hodgkin lymphoma (NHL) (n = 518 cases, 597 controls) among women in Connecticut, we analyzed one or more single nucleotide polymorphisms (SNPs) in ten candidate genes (AKR1A1, AKR1C1, AKR1C3, CYBA, GPX1, MPO, NOS2A, NOS3, OGG1, and SOD2) that mediate oxidative stress directly or indirectly in the NADPH oxidase-dependent respiratory burst.
  • Polymorphisms in AKR1A1 and CYBA were significantly associated with increased risk of NHL.
  • There was a 1.7-fold (95% CI = 1.2-2.4, P = 0.0047) increased risk of NHL for individuals who were variant homozygous for the AKR1A1 (IVS5 + 282T > C) SNP.
  • The effect was most pronounced for risk of diffuse large B-cell lymphoma, but risk estimates were non-significantly elevated for other common B-cell histologies and T-cell lymphomas as well.
  • In addition, individuals variant homozygous for the CYBA (Ex4 + 11C > T) SNP had a 1.6-fold (95% CI = 1.1-2.4, P = 0.019) increased risk of NHL that was particularly pronounced for T-cell lymphoma (OR = 3.5, 95% CI = 1.3-9.6, P = 0.013), but was also associated with non-significant increased risks for each of the common B-cell histologies.
  • These results suggest that SNPs in genes related to the oxidative stress pathway may be associated with increased risk of NHL.
  • [MeSH-major] Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Heterozygote. Homozygote. Humans. Middle Aged. Odds Ratio. Oxidative Stress. Risk


96. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma; 2008 Jun;49(6):1184-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.
  • HMGB1 expression was analysed in 18 non-Hodgkin lymphomas and two lymphoma cell lines.
  • Immunohistochemistry showed that HMGB1 positivity is confined to the lymphoma cells.
  • This protein can support the growth and angiogenesis of lymphoma cells in a paracrine way when released e.g. due to necrosis.
  • [MeSH-major] HMGB1 Protein / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Necrosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569640.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HMGB1 Protein; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


97. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ: Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol; 2006 May;133(3):293-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between non-Hodgkin lymphoma and haplotypes in the TNF region.
  • This study investigates a number of single nucleotide polymorphisms (SNPs) and microsatellite variants present within these genes in a large cohort of non-Hodgkin lymphoma (NHL) cases including 211 cases of follicular lymphoma (FL) and 281 cases of diffuse large B-cell lymphoma (DLBCL), and 478 unaffected controls.
  • The study investigated whether particular alleles at these loci, or their combination across the TNF region in the form of haplotypes, may act as markers for predisposition and development of NHL.
  • The study provided evidence for an influence of the TNF region in the susceptibility to NHL, whereby the loci -863, -857, TNFe and TNFd categorised five haplotype groups over which risk of both FL and DLBCL varied significantly.
  • [MeSH-major] Genetic Predisposition to Disease. Haplotypes. Lymphoma, Non-Hodgkin / genetics. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Genotype. Heteroduplex Analysis / methods. Humans. Linkage Disequilibrium. Lymphotoxin-alpha / genetics. Male. Microsatellite Repeats. Middle Aged. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643431.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lymphotoxin-alpha; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


98. Willett EV, Roman E: Obesity and the risk of Hodgkin lymphoma (United Kingdom). Cancer Causes Control; 2006 Oct;17(8):1103-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and the risk of Hodgkin lymphoma (United Kingdom).
  • OBJECTIVE: The aim of the study was to investigate the relationship between Hodgkin lymphoma (HL) and obesity.
  • METHODS: A population-based case-control study recruited incident cases of lymphoma in England during 1998-2003.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Risk Factors


99. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A: Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest; 2009 Dec;89(12):1364-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Aurora B kinase in non-Hodgkin lymphoma.
  • This study explored the levels of Aurora B, a key regulator of mitosis, in 71 lymph nodes and tumor specimens excised operatively from individuals with various types of non-Hodgkin lymphoma (NHLs).
  • Immunohistochemical examination found that diffuse large B-cell lymphoma (10/21, 48%) and Burkitt lymphoma (BL) (6/7, 86%) cells highly (percentage of positive cells, >20%) expressed Aurora B in their nuclei.
  • On the other hand, none of the low-grade B-cell lymphoma (n=20), except for one case of follicular lymphoma, highly expressed this protein kinase, suggesting that levels of Aurora B correlated with histological grade in B-cell NHLs (P<0.01).
  • [MeSH-major] Lymphoma, Non-Hodgkin / enzymology. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Aurora Kinase B. Aurora Kinases. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Synergism. Enzyme Activation. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Middle Aged. Organophosphates / pharmacology. Phosphorylation. Quinazolines / pharmacology. Signal Transduction / drug effects. Tubulin Modulators / pharmacology. Vincristine / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823168.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 0 / Organophosphates; 0 / Quinazolines; 0 / Tubulin Modulators; 5J49Q6B70F / Vincristine; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down


100. Mitterlechner T, Fiegl M, Mühlböck H, Oberaigner W, Dirnhofer S, Tzankov A: Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol; 2006 Jan;59(1):48-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.
  • AIMS: To analyse the entity specific incidence and disease specific survival (DSS) of non-Hodgkin lymphomas (NHLs) in Tyrol/Austria, 1991-2000.
  • RESULTS: NHL more frequently affected men (male/female ratio, 1.52).
  • There was a significant increase in diffuse large B cell lymphoma (DLBCL) and decrease in CLL/SLL in men, and a decrease in MM in women.
  • Age, T-NHL, lambda light chain restriction in MM, and male sex in CLL/SLL were associated with poor prognosis.
  • In B-NHL, DSS decreased in the following order: hairy cell leukaemia, marginal zone lymphoma, follicular lymphoma, Burkitt lymphoma, ALL, DLBCL, CLL, MM, and mantle cell lymphoma.
  • CONCLUSIONS: The incidence of NHL in Tyrol has changed in the past decade, with a significant increase in DLBCL, decrease in CLL/SLL in men, and decrease in MM in women.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Austria / epidemiology. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Sex Distribution

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Am J Epidemiol. 1998 Nov 1;148(9):833-41 [9801013.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):361-8 [11319177.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Oncologist. 2001;6(3):247-56 [11423671.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):50-5 [11753078.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] Biomed Pharmacother. 2002 Jul;56(5):223-34 [12199621.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):1071-7 [12199787.001]
  • [Cites] Dtsch Med Wochenschr. 2002 Oct 25;127(43):2253-8 [12397539.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):892 [12461049.001]
  • [Cites] J Mol Cell Cardiol. 2002 Dec;34(12):1595-607 [12505058.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):193 [12610096.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3181-7 [12515730.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):451-8 [12688314.001]
  • [Cites] Can J Gastroenterol. 2003 Jun;17 Suppl B:49B-52B [12845352.001]
  • [Cites] Autoimmun Rev. 2003 May;2(3):119-25 [12848952.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):99-105 [12925963.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1704-6 [14594618.001]
  • [Cites] Br J Haematol. 2004 May;125(3):294-317 [15086411.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1215-21 [15277261.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):227-38 [15322489.001]
  • [Cites] Blood. 1976 Jul;48(1):41-51 [820387.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):755-6 [2210891.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):163-4 [1728608.001]
  • [Cites] Am J Public Health. 1992 Jul;82(7):990-7 [1609918.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5453s-5455s [1394153.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5465s-5467s [1327508.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2386-9 [8162585.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1707-15 [9846961.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):155-63 [10319384.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):627-33 [10492638.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):698-706 [10505027.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Immunology. 2005 Jan;114(1):37-43 [15606793.001]
  • [Cites] Transfus Med Rev. 2000 Jul;14(3):258-68 [10914420.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):12-20 [10561013.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):21-5 [10561014.001]
  • [Cites] Cancer Causes Control. 1999 Dec;10(6):617-25 [10616830.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):713-5 [7917925.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1753-7 [8983286.001]
  • [Cites] Ann Intern Med. 1997 Sep 1;127(5):365-71 [9273827.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Transfusion. 1997 Oct;37(10):1084-92 [9354830.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):49-56 [9486463.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):621-5 [9681531.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1184-91 [9777980.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Haematologica. 2001 Jan;86(1):58-63 [11146572.001]
  • (PMID = 16394280.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860250
  •  go-up   go-down






Advertisement